Table 4 Treatments and outcomes of patients in the four groups

Admission to intensive care unit

10 (10%)

8 (15%)

2 (18%)

0

0.30

0.72

1.0

< 0.0001

Secondary infection

0

1 (2%)

0

1 (0.3%)

0.34

··

1.0

1

Shock

1 (1%)

2 (4%)

0

0

0.54

1.0

1.0

0.211

Treatment

 TCM treatment

93 (90%)

47 (90%)

11 (100%)

381 (99%)

0.99

0.60

0.58

< 0.0001

 Immunotherapy

35 (34%)

37 (71%)

9 (82%)

143 (37%)

< 0.0001

0.0056

0.73

0.542

 Antiviral treatment

16 (16%)

35 (67%)

5 (45%)

8 (2%)

< 0.0001

0.043

0.31

< 0.0001

 Antibiotics

16 (16%)

40 (77%)

2 (18%)

11 (3%)

< 0.0001

1.0

0.001

< 0.0001

 Heparin

26 (25%)

6 (12%)

6 (55%)

33 (9%)

0.16

1.0

0.58

0

 Plasma of recovered patients

2 (2%)

2 (4%)

1 (9%)

NA

0.87

0.16

0.44

··

 Corticosteroid and gamma globulin

0

2 (4%)

0

NA

0.11

0.0021

0.44

··

 Glucocorticoids alone

0

8 (15%)

0

0

< 0.0001

··

0.37

··

 Continuous renal-replacement therapy

0

3 (6%)

0

0

0.014

··

1.0

··

Oxygen support

 Nasal cannula

17 (17%)

7 (13%)

2 (18%)

4 (1%)

0.62

1.0

1.0

< 0.0001

 Non-invasive ventilation or high-flow nasal cannula

2 (2%)

5 (9%)

1 (9%)

0

0.078

0.27

1.0

< 0.0001

 Invasive mechanical ventilation

2 (2%)

2 (4%)

0

0

0.87

1.0

1.0

0.014

 Invasive mechanical ventilation and ECMO

2 (2%)

2 (4%)

0

0

0.87

1.0

1.0

0.014

Prognosis

 Hospitalisation

0

0

0

0

··

··

··

··

 Discharge

103 (100%)

52 (100%)

11 (100%)

384 (100%)

··

··

··

··

 Death

0

0

0

0

··

··

··

··

 LOS, days

26 (18–46)

45.0 (22.0-91.5)

51 (40–71)

19 (15–25)

0.018

0.008

0.993

< 0.0001

 Disease duration

28 (21–47)

50 (26.5–96.5)

55 (40–73)

22 (17–28)

0.007

0.006

0.990

< 0.0001